Comparison of Adjuvant Target Therapy, Immunotherapy, and Chemotherapy for Resected EGFR-Mutant NSCLC – an Updated Network Meta-Analysis of 3300 Patients
Guang-Ling Jie,Hong-Lian Lu,Si-Yang Liu,Jia-Tao Zhang,Zhi-Hong Chen,Song-Rong Wang,Hong-Xia Tian,Song Dong,Ri-Qiang Liao,Wen-Zhao Zhong,Xue-Ning Yang,Si-Yang Maggie Liu,Yi-Long Wu
DOI: https://doi.org/10.2139/ssrn.4153830
2022-01-01
Abstract:Background: Multiple adjuvant treatment strategies are available for resected epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), but what is the preferred method among these strategies remain unsolved. Methods: A network meta-analysis was performed to investigate the efficacy and safety of targeted therapy, immunotherapy, and chemotherapy for resected EGFR-mutant NSCLC. Electronic databases were searched using relevant keywords. Randomized controlled trials comparing two adjuvant treatments for resected EGFR-mutant NSCLC patients were included. The primary endpoint was disease-free survival (DFS), and secondary endpoints were overall survival (OS) and grade ≥3 adverse events (AEs). Findings: Thirteen eligible trials involving 3300 patients and six treatment strategies were included. All EGFR-TKIs-based adjuvant therapies, including osimertinib (hazard ratio [HR]=0.23, 95% confidence interval [CI]: 0.16-0.33), chemotherapy followed by first-generation EGFR-TKI (Chemo-TKI; HR=0.34, 95% CI: 0.16-0.69), first-generation EGFR-TKIs (1st EGFR-TKI; HR=0.62, 95%CI: 0.52-0.74), can provide significant DFS benefits compared with chemotherapy for EGFR-mutant NSCLC patients. Adjuvant immunotherapy did not improve DFS compared with chemotherapy. (HR=0.98, 95% CI: 0.64-1.50). In patients who were treated with adjuvant 1st EGFR-TKI, previous chemotherapy did not improve the DFS (0.54, 0.26-1.14) and OS (0.83, 0.15-4.52) benefit. In addition, no OS improvements were identified when comparing all the EGFR-TKI-based treatments with chemotherapy (HR=0.76, 95% CI: 0.14-4.12 for Chemo-TKI; HR=0.94, 95% CI: 0.73-1.22 for EGFR-TKIs monotherapy). Osimertinib showed the fewest toxic effects, whereas Chemo-TKI caused the most toxicity. In subgroup analysis, patients with EGFR exon 19 deletion, stage III disease, and adenocarcinoma can benefit more from adjuvant EGFR-TKIs therapy. Interpretation: EGFR-TKIs-based adjuvant therapies can provide a significant DFS benefit compared with immunotherapy or chemotherapy for resected EGFR-mutant NSCLC, especially osimertinib. Adjuvant immunotherapy failed to show a DFS benefit versus chemotherapy. Adjuvant EGFR-TKIs could be an important treatment option for resected early-stage EGFR-mutant NSCLC, regardless of previous chemotherapy. Funding: None.Declaration of Interest: Yi-Long Wu reports consulting and advisory services and declares speaker fees for Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, Merck Sharp & Dohme,and Bristol Myers Squibb. All other authors declare that they have no conflict of interest.